Red blood cell-derived extracellular vesicles (RBCEVs) provide a scalable, non-viral platform for gene therapy. High-grade RBCEVs purified using tangential flow filtration can deliver sizable plasmids and mediate sustained in vivo expression of therapeutic proteins, including factor IX and Herceptin, highlighting their potential use for safe and efficient gene therapy.